Does the media prefer RYTM or VIR?

In the previous week, Vir Biotechnology had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Vir Biotechnology and 6 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.61 beat Vir Biotechnology's score of 0.41 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MIRM or VIR?

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 8 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 1.08 beat Vir Biotechnology's score of 0.41 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TGTX or VIR?

In the previous week, TG Therapeutics had 5 more articles in the media than Vir Biotechnology. MarketBeat recorded 13 mentions for TG Therapeutics and 8 mentions for Vir Biotechnology. TG Therapeutics' average media sentiment score of 0.74 beat Vir Biotechnology's score of 0.41 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VIR or CNTA?

In the previous week, Vir Biotechnology had 4 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 8 mentions for Vir Biotechnology and 4 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat Vir Biotechnology's score of 0.41 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vir Biotechnology (VIR) Competitors

$8.77 +0.03 (+0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$8.74 -0.03 (-0.39%)

As of 07:56 PM Eastern

Compare

VIR vs. RYTM, MIRM, TGTX, CNTA, and SRRK

Should you buy Vir Biotechnology stock or one of its competitors? MarketBeat compares Vir Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vir Biotechnology include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), TG Therapeutics (TGTX), Centessa Pharmaceuticals (CNTA), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Vir Biotechnology compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

65.3% of Vir Biotechnology shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals presently has a consensus target price of $131.81, indicating a potential upside of 55.60%. Vir Biotechnology has a consensus target price of $20.38, indicating a potential upside of 132.33%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Rhythm Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	30.59	-$196.54M	-$3.13	N/A
Vir Biotechnology	$68.56M	21.57	-$437.99M	-$3.13	N/A

In the previous week, Vir Biotechnology had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Vir Biotechnology and 6 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.61 beat Vir Biotechnology's score of 0.41 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rhythm Pharmaceuticals beats Vir Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Mirum Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus target price of $137.64, indicating a potential upside of 49.56%. Vir Biotechnology has a consensus target price of $20.38, indicating a potential upside of 132.33%. Given Vir Biotechnology's higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

65.3% of Vir Biotechnology shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.77	-$23.36M	-$13.61	N/A
Vir Biotechnology	$68.56M	21.57	-$437.99M	-$3.13	N/A

Mirum Pharmaceuticals has a net margin of -140.24% compared to Vir Biotechnology's net margin of -638.88%. Mirum Pharmaceuticals' return on equity of -11.28% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 8 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 1.08 beat Vir Biotechnology's score of 0.41 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Vir Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Vir Biotechnology compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TG Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Vir Biotechnology's net margin of -638.88%. TG Therapeutics' return on equity of 88.73% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

TG Therapeutics has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.96	$447.18M	$2.86	14.02
Vir Biotechnology	$68.56M	21.57	-$437.99M	-$3.13	N/A

In the previous week, TG Therapeutics had 5 more articles in the media than Vir Biotechnology. MarketBeat recorded 13 mentions for TG Therapeutics and 8 mentions for Vir Biotechnology. TG Therapeutics' average media sentiment score of 0.74 beat Vir Biotechnology's score of 0.41 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics currently has a consensus target price of $52.50, suggesting a potential upside of 30.89%. Vir Biotechnology has a consensus target price of $20.38, suggesting a potential upside of 132.33%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

TG Therapeutics beats Vir Biotechnology on 11 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Vir Biotechnology (NASDAQ:VIR) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Vir Biotechnology had 4 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 8 mentions for Vir Biotechnology and 4 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat Vir Biotechnology's score of 0.41 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vir Biotechnology currently has a consensus target price of $20.38, indicating a potential upside of 132.33%. Centessa Pharmaceuticals has a consensus target price of $41.33, indicating a potential upside of 3.72%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Vir Biotechnology is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Centessa Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	21.57	-$437.99M	-$3.13	N/A
Centessa Pharmaceuticals	$15M	396.45	-$197.53M	-$1.79	N/A

Vir Biotechnology has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Summary

Vir Biotechnology beats Centessa Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Scholar Rock has higher earnings, but lower revenue than Vir Biotechnology. Scholar Rock is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Vir Biotechnology	$68.56M	21.57	-$437.99M	-$3.13	N/A

Scholar Rock currently has a consensus target price of $56.00, indicating a potential upside of 25.45%. Vir Biotechnology has a consensus target price of $20.38, indicating a potential upside of 132.33%. Given Vir Biotechnology's higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Scholar Rock has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Vir Biotechnology had 7 more articles in the media than Scholar Rock. MarketBeat recorded 8 mentions for Vir Biotechnology and 1 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.87 beat Vir Biotechnology's score of 0.41 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Overall Sentiment
Scholar Rock	Very Positive
Vir Biotechnology	Neutral

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Summary

Scholar Rock and Vir Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIR vs. The Competition

Export

Metric	Vir Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.47B	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-2.80	9.91	18.89	22.53
Price / Sales	21.57	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	1.59	6.63	9.84	6.72
Net Income	-$437.99M	$24.20M	$3.57B	$337.19M
7 Day Performance	-3.63%	-3.24%	-1.16%	0.48%
1 Month Performance	-12.30%	0.53%	3.85%	5.07%
1 Year Performance	67.53%	47.24%	27.40%	34.25%

Vir Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIR Vir Biotechnology	1.8199 of 5 stars	$8.77 +0.3%	$20.38 +132.3%	+72.4%	$1.47B	$68.56M	N/A	580	Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.761 of 5 stars	$87.84 flat	$131.81 +50.1%	+32.5%	$6.02B	$189.76M	N/A	140	Analyst Forecast
MIRM Mirum Pharmaceuticals	3.738 of 5 stars	$98.62 flat	$137.08 +39.0%	+100.5%	$6.01B	$521.31M	N/A	140	Positive News Analyst Forecast Insider Trade
TGTX TG Therapeutics	3.8957 of 5 stars	$38.87 flat	$52.50 +35.1%	+2.5%	$5.95B	$616.29M	13.59	290	Analyst Upgrade Gap Up
CNTA Centessa Pharmaceuticals	2.1382 of 5 stars	$39.75 flat	$40.70 +2.4%	+197.5%	$5.93B	$15M	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIR) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Competitors

VIR vs. RYTM, MIRM, TGTX, CNTA, and SRRK

How does Vir Biotechnology compare to Rhythm Pharmaceuticals?

Summary

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Summary

How does Vir Biotechnology compare to TG Therapeutics?

Summary

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Summary

How does Vir Biotechnology compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Competitors

VIR vs. RYTM, MIRM, TGTX, CNTA, and SRRK

How does Vir Biotechnology compare to Rhythm Pharmaceuticals?

Do institutionals and insiders have more ownership in RYTM or VIR?

Do analysts recommend RYTM or VIR?

Which has more volatility and risk, RYTM or VIR?

Is RYTM or VIR more profitable?

Which has preferable valuation & earnings, RYTM or VIR?

Does the media prefer RYTM or VIR?

Summary

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Which has more risk and volatility, MIRM or VIR?

Do analysts rate MIRM or VIR?

Do institutionals & insiders have more ownership in MIRM or VIR?

Which has preferable valuation and earnings, MIRM or VIR?

Is MIRM or VIR more profitable?

Does the media prefer MIRM or VIR?

Summary

How does Vir Biotechnology compare to TG Therapeutics?

Do insiders and institutionals hold more shares of TGTX or VIR?

Which has more volatility & risk, TGTX or VIR?

Is TGTX or VIR more profitable?

Which has preferable earnings and valuation, TGTX or VIR?

Does the media refer more to TGTX or VIR?

Do analysts recommend TGTX or VIR?

Summary

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Is VIR or CNTA more profitable?

Do insiders and institutionals have more ownership in VIR or CNTA?

Does the media prefer VIR or CNTA?

Do analysts rate VIR or CNTA?

Which has preferable valuation & earnings, VIR or CNTA?

Which has more risk and volatility, VIR or CNTA?

Summary

How does Vir Biotechnology compare to Scholar Rock?

Which has higher earnings and valuation, SRRK or VIR?

Do analysts rate SRRK or VIR?

Is SRRK or VIR more profitable?

Does the media refer more to SRRK or VIR?

Do insiders & institutionals believe in SRRK or VIR?

Which has more risk & volatility, SRRK or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools